Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Hospira, Inc.    HSP   US4410601003


News SummaryMost relevantAll newsSector news 

Hospira : Applauds Delaware Governor’s Signing of Biosimilars Legislation

05/30/2014 | 12:42pm US/Eastern

LAKE FOREST, Ill., May 30, 2014 - Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today commended Delaware Gov. Jack Markell for his decision to sign Senate Substitute 1 for Senate Bill 118. This law creates a pathway for the substitution of interchangeable biologic drugs and helps pave the way for patient access to cost savings from biosimilar products.

When biosimilars become available in the United States in the coming years, clinicians will have opportunities to provide their patients with greater accessibility to effective and more affordable biologic drugs. The introduction of biosimilars could help the United States save up to $250 billion over 10 years, according to one report.

"The introduction of biosimilars promises to help put new cost-savings in the hands of patients and states, such as Delaware, that are taking early action to establish clear and transparent policies for the substitution of these high-quality and more affordable biologic products," said Paul Audhya, M.D., vice president, Medical Affairs, Hospira.

The governor's signature on Senate Substitute 1 for Senate Bill 118 allows pharmacists to substitute biosimilars for prescribed biological reference products unless the prescribing physician expressly requests the reference biologic.

Hospira is a market leader in biosimilars in Europe, and expects to submit its first biosimilar to the U.S. Food and Drug Administration (FDA) later this year or in early 2015.

distributed by
React to this article
Latest news on HOSPIRA, INC.
03/30 HOSPIRA : INFLECTRA™ (Infliximab) Now Available in Canada
03/30 HOSPIRA : INFLECTRA(TM) (Infliximab) Now Available in Canada
03/27 HOSPIRA : first biosimilar could be its first to gain FDA approval
03/27 HOSPIRA : McPherson, Kansas Company Applies to DEA to Import Controlled Substanc..
03/27 HOSPIRA : Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates..
03/27 Importer of Controlled Substances Application: HOSPIRA (Importer of Controlle..
03/18 HOSPIRA : Statement on FDA Approval of the First Biosimilar in the United States
03/15 PFENEX : Reports Fourth Quarter and Full Year 2014 Results and Provides Business..
03/13 HOSPIRA : Chicago Tribune Phil Rosenthal column
03/06 HOSPIRA : Inflectra™ (infliximab) patient registry reports interim results..
Duration : Period :
Hospira, Inc. Technical Analysis Chart | HSP | US4410601003 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes